During more than 30 years of extensive research, Sangart has refined the pegylation of human hemoglobin to create a proprietary molecule, MP4. The MP4 gas-delivery platform is being used to develop targeted ischemic rescue therapies for patients in crisis who are experiencing ischemia (oxygen deprivation of tissues) and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occulsive crisis associated with sickle cell disease.
MP4OX is a targeted ischemic rescue therapy being developed to treat trauma patients experiencing hemorrhagic shock. It has been designed to improve perfusion and delivery oxygen to tissues in crisis due to ischemia.
Please click here for a short animation describing MP4OX's unique mechanism of action.
MP4CO is a targeted ischemic rescue therapy for sickle cell vaso-occlusive crisis. It has been designed to improve perfusion and limit progression of the vaso-occulsive crisis associated with sickle cell disease, based on its anti-sickling, anti-inflammatory and anti-ischemic properties.
Sangart is developing a number of additional, earlier stage pipeline products based on its core technology and unique understanding of oxygen delivery.
Built on a strong foundation of scientific research, Sangart is dedicated to continuing its comprehensive clinical trial program to study and develop its products for patients in need.
Studying MP4OX's ability to benefit patients suffering from trauma.
Studying MP4CO's ability to benefit sickle cell anemia patients.Please click here for a broadcast segment on sickle cell disease featuring Sangart.